Regenxbio Inc
RGNX
Get informed when a big investor buys or sells
+ FollowMarket Cap$403.24M
Close$
$25.02
151.4% upside
Current Fair Value
151.4% upsideUndervalued by 151.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $403.24 Million |
|---|---|
| Enterprise Value | $465.00 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.76 |
| Beta | 1.03 |
| Outstanding Shares | 52,428,000 |
Return
| Return on Equity | -1375.64% |
|---|---|
| Return on Assets | -84.83% |
| Return on Invested Capital | -93.54% |
Valuation & Multiples
| P/E Ratio | -1.41 |
|---|---|
| PEG | 0.09 |
| Price to Sales | 9.95 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.29 |
| Enterprise Value to EBIT | -1.84 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 3.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.36
Average shareholder expectationRevenue Estimate
$25.84 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.29
Average shareholder expectationRevenue Estimate
$111.85 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6778▼ 10.11% |
|---|---|
| Total Calls | 414,900▲ 131.66% |
| Total Puts | 281,200▲ 101.58% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 82.58%▲ 2.98% |
|---|---|
| Total Invested | $355.13M▼ 40.13% |
| Investors Holding | 188▲ 3.00% |
ESG Score
No data
About Regenxbio Inc
CEO: Kenneth Mills